An Overview of Nonketotic Hyperglycinemia (NKH)

Table of Contents
View All
Table of Contents

Nonketotic hyperglycinemia (NKH) is a genetic condition that can lead to serious neurological problems, coma, and death. “Hyperglycinemia” refers to abnormally high levels of a molecule, glycine. The word “nonketotic” distinguishes NKH from certain other health conditions that can cause increased glycine. The condition is also sometimes called "glycine encephalopathy," meaning a disease that damages the brain.

NKH belongs to a larger group of medical conditions called “inborn errors of metabolism.” These are genetic defects that lead to problems making certain chemical conversions in the body. NKH is a rare condition: it is diagnosed in roughly one in 60,000 newborns. However, it may be more common in specific subpopulations, like in certain areas of Israel.

nonketonic hyperglycinemia diagnosis
Verywell/Emily Roberts


People with NKH can have variable intensity and degree of symptoms. Researchers aren’t yet sure why, but boys tend to have less severe symptoms compared to girls, and they are more likely to survive. Most commonly, symptoms begin soon after birth. These infants show symptoms like the following:

Common Form Symptoms

  • Lack of energy (lethargy)
  • Feeding difficulties
  • Low muscle tone
  • Abnormal muscle jerks
  • Hiccoughs
  • Temporarily stopped breathing

Symptoms may worsen, leading to a total lack of responsiveness and coma. Unfortunately, death is not uncommon. When infants survive this initial period, the affected individuals almost always have additional symptoms. For example, these might include severe developmental disability or seizures that are very difficult to treat.

Less commonly, people may suffer from an atypical form of the disease. In some of these atypical cases, the disease is milder. For example, the individual might have intellectual disability, but not nearly as severely.

In the most common of the atypical forms, symptoms begin later in infancy, but in other cases, symptoms may not begin until later in childhood. These people may appear normal but then develop symptoms that affect primarily the nervous system. These might include:

Atypical Form Symptoms

  • Seizures
  • Abnormal muscle movements
  • Intellectual disability
  • Behavioral issues
  • Attention-hyperactivity disorder
  • Scoliosis
  • Swallowing dysfunction
  • Abnormal muscle tightness
  • Gastroesophageal reflux
  • Other nervous system problems

For people whose symptoms begin in infancy, about 50% will have a more mild form of the disease.

Extremely rarely, infants experience something called “transient NKH." Some experts consider this a controversial diagnosis. In these cases, glycine levels are very high at birth, but for unknown reasons, they then decrease to normal or near-normal levels. These infants may experience temporary symptoms that completely go away by the age of two months.

In other cases, individuals with transient NKH go on to experience some long-term problems, like intellectual disability. Researchers aren’t sure how to explain this very uncommon form of the disease. It may be that it results from slow maturation of the enzyme that is affected in other forms of NKH.


The symptoms of NKH result from abnormally high levels of glycine, a small molecule. Glycine is a normal amino acid, one of the components used to make proteins in your body. Glycine also normally plays an important role in the nervous system, where it serves as a chemical messenger for various signals.

Glycine performs many important physiological roles. However, if levels of glycine become too high, it can lead to problems. Overstimulation of glycine receptors and the death of neurons can lead to some of the symptoms of the condition.

Normally, glycine is broken down by an enzyme before levels build up too high. When there is a problem with this enzyme (called the glycine cleavage system), NKH can result. This is caused by abnormal genetic mutations in one of the proteins used to make the enzyme. Most of the time this is due to a mutation in one of two genes—the AMT or the GLDC gene.

Because of these mutations, excess glycine builds up in the body, particularly the brain and the rest of the nervous system, which leads to the symptoms of NKH. It’s thought that people with the milder version of NKH may have more minor problems with the glycine cleavage system. This prevents glycine levels from getting as high as they do in people with the severe form of the disease.


Diagnosis of NKH can be challenging. A physical exam and one's medical history play an important role in the diagnosis. In infants with symptoms like low muscle tone, seizures, and coma, healthcare providers need to consider the possibility of NKH. Healthcare providers also need to rule out the possibility of medical conditions that can cause similar symptoms. A wide variety of syndromes can cause problems like seizures in infants, including many different genetic problems.

It’s often helpful to work with a specialist in rare childhood genetic diseases if NKH or another genetic problem is a concern.

Testing plays an important role in diagnosis. Some of the key tests check for elevated levels of glycine. This might include tests of glycine in the blood, urine, or cerebrospinal fluid. However, certain medical conditions can mimic some of the laboratory findings of NKH. These include other rare disorders of metabolism, including propionic acidemia and methylmalonic acidemia. Treatment with certain anti-epileptic drugs, like valproate, can also confuse the diagnosis, since they may also cause elevated levels of glycine.

To confirm a diagnosis of NKH, genetic tests (from a blood or tissue sample) can check for abnormalities in one of the genes known to cause NKH. Less commonly, a liver biopsy might also be needed to confirm the diagnosis.

As part of the diagnosis, it’s also important to assess how much damage has been done from NKH. For example, this might require tests like MRI of the brain or an EEG. It’s also important to have specialists perform neurological and developmental assessments.


Infants with NKH are usually very ill and require treatment in a neonatal intensive care unit (NICU). Here they can receive high levels of intervention and care.

An infant that survives the initial critical period will need life-long attention from medical specialists, including neurologists and developmental experts.

Unfortunately, there is no real treatment for the more common and severe forms of NKH. However, for people with less severe disease, there are some treatments that may help somewhat. These are most likely to provide some benefit if they are given early and aggressively. These include:

  • Drugs to lower the levels of glycine (sodium benzoate)
  • Drugs that oppose the action glycine at certain neurons (like dextromethorphan or ketamine)

It’s also important to treat seizures in NKH. These can be very difficult to address with standard medications such as phenytoin or phenobarbital. Successful treatment may require a combination of antiepileptic medications. Sometimes other interventions may be needed to help control seizures, like vagal nerve stimulators or special diets.

Treatment for Other Symptoms

Other symptoms of NKH also need to be addressed. These might include:

  • Mechanical ventilation (for early breathing problems)
  • Gastronomy tube (so infants with swallowing problems can receive nourishment)
  • Physical therapy (for muscle problems)
  • Interventions to maximize intellectual performance and autonomy

It’s also worth investigating the possibility of clinical trials. Ask your healthcare provider or search the government database for clinical trials to see if there are medical studies that might benefit your child.


NKH is an autosomal recessive genetic condition. That means a person with NKH has to receive an affected gene from both their mother and their father. People with only one affected gene do not get the condition.

If a mother and father both have a single affected gene, they have a 25 percent chance of having a child born with NKH. There is a 50 percent chance that their child would be a carrier for NKH without having symptoms.

Much less commonly, NKH can arise from a sporadic mutation. That just means that a child can rarely be born with NKH, even if only one of their parents carries the affected mutation.

Working with a genetic counselor is often very helpful if someone in your family was born with NKH. This professional can give you a sense of the risks in your particular situation. Prenatal testing is also available if there is a risk of NKH. In vitro fertilization may also be an option for couples who want to pre-screen embryos for the disease.

A Word From Verywell

A diagnosis of NKH is a devastating one for families. It can be overwhelming to learn that your young child has a disease for which there is very little treatment. It is tragic to lose one’s child; children that do survive will need a lifetime of support and care. Networking with other families can be a powerful way to get information and a sense of connection. Know that your healthcare team is here to support you in whatever way is possible. Don’t hesitate to reach out to your support system whenever you need to.

6 Sources
Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Hennermann JB. Clinical variability in glycine encephalopathy. Future Neurol. 2006;1(5):621-630.

  2. Van Hove JLK, Coughlin C II, Swanson M, et al. Nonketotic hyperglycinemia. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews.

  3. Hennermann JB, Berger JM, Grieben U, et al. Prediction of long-term outcome in glycine encephalopathy: a clinical survey. J Inherit Metab Dis. 2012;35(2):253-61. doi:10.1007/s10545-011-9398-1

  4. Aliefendioğlu D, Tana Aslan Ay, Coşkun T, et al. Transient nonketotic hyperglycinemia: two case reports and literature review. Pediatr Neurol. 2003;28(2):151-5.  doi:10.1016/s0887-8994(02)00501-5

  5. Coughlin CR, Swanson MA, Kronquist K, et al. Correction: The genetic basis of classic nonketotic hyperglycinemia due to mutations in GLDC and AMT. Genet Med. 2018;20(9):1098. doi:10.1038/gim.2017.232

  6. Agana M, Frueh J, Kamboj M, et al. Common metabolic disorder (inborn errors of metabolism) concerns in primary care practiceAnn Transl Med. 2018;6(24):469. doi:10.21037/atm.2018.12.34

Additional Reading

By Ruth Jessen Hickman, MD
Ruth Jessen Hickman, MD, is a freelance medical and health writer and published book author.